Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2025)

Foghorn Therapeutics has reported Total Non-Current Liabilities over the past 6 years, most recently at $306.0 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $306.0 million for Q4 2025, down 7.12% from a year ago — trailing twelve months through Dec 2025 was $306.0 million (down 7.12% YoY), and the annual figure for FY2025 was $306.0 million, down 7.12%.
  • Total Non-Current Liabilities for Q4 2025 was $306.0 million at Foghorn Therapeutics, up from $294.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for FHTX hit a ceiling of $422.8 million in Q4 2021 and a floor of $104.9 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $370.8 million (2023), compared with a mean of $349.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 290.36% in 2022 and later fell 10.29% in 2023.
  • Foghorn Therapeutics' Total Non-Current Liabilities stood at $422.8 million in 2021, then decreased by 4.26% to $404.7 million in 2022, then fell by 10.29% to $363.1 million in 2023, then fell by 9.25% to $329.5 million in 2024, then dropped by 7.12% to $306.0 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $306.0 million (Q4 2025), $294.0 million (Q3 2025), and $302.1 million (Q2 2025) per Business Quant data.